Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.18)
# 2,838
Out of 5,113 analysts
75
Total ratings
43.86%
Success rate
7.64%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $22 → $20 | $26.20 | -23.66% | 17 | May 8, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $22.53 | -33.42% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $15.47 | -48.29% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $26.82 | +86.43% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $133.89 | +1.58% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $6.99 | +128.90% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $9.73 | +537.20% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $1.95 | +515.38% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $22.17 | +391.66% | 3 | Dec 12, 2023 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $8 | $2.72 | +194.12% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.90 | +156.41% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $12.60 | +693.65% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $24.53 | -75.54% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $7.32 | +186.89% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $162.64 | -85.86% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $49.73 | -27.61% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
May 8, 2025
Maintains: Hold
Price Target: $22 → $20
Current: $26.20
Upside: -23.66%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $22.53
Upside: -33.42%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $15.47
Upside: -48.29%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $26.82
Upside: +86.43%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $133.89
Upside: +1.58%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $6.99
Upside: +128.90%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $9.73
Upside: +537.20%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $1.95
Upside: +515.38%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $22.17
Upside: +391.66%
Acumen Pharmaceuticals
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $2.72
Upside: +194.12%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.90
Upside: +156.41%
Nov 11, 2022
Maintains: Buy
Price Target: $140 → $100
Current: $12.60
Upside: +693.65%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $24.53
Upside: -75.54%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $7.32
Upside: +186.89%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $162.64
Upside: -85.86%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $49.73
Upside: -27.61%